Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5977259 | 0.98 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL5977199 | 0.98 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL3044294 | 0.98 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL5979524 | 0.98 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL5978450 | 0.98 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL5978990 | 0.98 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL5976933 | 0.98 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL5978617 | 0.98 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL5360417 | 0.93 | — | — | |
| SCHEMBL1050327 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4119665-A | Manufacture of 6-aminocaproamide | BASF AKTIENGESELLSCHAFT (DE) | 1978-10-10 | — | — | US | claimed |
| JP-6316555-A | — | — | None | — | — | JP | disclosed |
| CN-116655494-A | Preparation method of adiponitrile | 重庆华峰化工有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11742522-B2 | Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery | MURATA MANUFACTURING CO., LTD. (JP) | 2023-08-29 | — | — | US | disclosed |
| US-11742522-B2 | Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery | MURATA MANUFACTURING CO., LTD. (JP) | 2023-08-29 | — | — | US | disclosed |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210320333-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | MURATA MANUFACTURING CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| WO-2020168152-A2 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-0373579-A1 | Manufacture of 5-cyanovaleric acid and its esters using cyclic cosolvents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-06-20 | — | — | EP | disclosed |
| US-4933483-A | Manufacture of 5-cyanovaleric acid and its esters | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-06-12 | — | — | US | disclosed |
| US-4508660-A | Carbonylation of olefinically unsaturated nitriles and acids using a sulfone solvent | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-02 | — | — | US | disclosed |
| EP-0023751-B1 | PROCESS FOR PRODUCING FIVE, SIX OR SEVEN MEMBERED SATURATED NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS | THE STANDARD OIL COMPANY (US) | 1983-12-14 | — | — | EP | disclosed |
| US-4393215-A | Cleavage of dialkoxyketoxime | ALLIED CORPORATION (US) | 1983-07-12 | — | — | US | disclosed |
| US-4301090-A | USING A POLYAMINE LIGAND PROMOTER TO FORM ESTERS, ALDEHYDES, AND AMIDES | STANDARD OIL COMPANY | 1981-11-17 | — | — | US | disclosed |
| US-4250093-A | HYDROGENATION-CYCLIZATION OF B-, G-, OR D-CYANO ESTERS USING A RUTHENIUM OR IRON METAL CATALYST | THE STANDARD OIL COMPANY (OHIO) | 1981-02-10 | — | — | US | disclosed |
| US-4235744-A | Carbonylation of olefinically unsaturated compounds | STANDARD OIL COMPANY (OHIO) (US) | 1980-11-25 | — | — | US | disclosed |
| US-4119665-A | Manufacture of 6-aminocaproamide | BASF AKTIENGESELLSCHAFT (DE) | 1978-10-10 | — | — | US | disclosed |
| US-4060543-A | Manufacture of 5-cyanovaleric acid and its esters | BASF AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | TSHR 798/4885LMNA 4193/4885ALDH1A1 2862/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | TSHR 798/4885LMNA 4193/4885ALDH1A1 2862/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | TSHR 798/4885LMNA 4193/4885ALDH1A1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.